Abstract:Abstract Proteasome inhibition with bortezomib has been reported to exert an immunomodulatory action in chronic autoimmune neuropathies. However, bortezomib used for the treatment of multiple myeloma induces a painful toxic polyneuropathy at a higher concentration. Therefore, we addressed this controversial effect and evaluated the neurotoxic and immunomodulatory mode of action of bortezomib in experimental autoimmune neuritis. Bortezomib-induced neuropathy was investigated in Lewis rats using the von Frey hair test, electrophysiological, qPCR and histological analyses of the sciatic nerve as well as dorsal root ganglia outgrowth studies. The immunomodulatory potential of bortezomib was characterized in Lewis rats after experimental autoimmune neuritis induction with P253-78 peptide. Clinical, electrophysiological, histological evaluation, von Frey hair test, flow cytometric and mRNA analyses were used to unravel the underlying mechanisms. We defined the toxic concentration of 0.2 mg/kg bortezomib applied intraperitoneally at Days 0, 4, 8 and 12. This dosage induces a painful toxic neuropathy but preserves axonal regeneration in vitro. Bortezomib at a concentration of 0.05 mg/kg significantly ameliorated experimental autoimmune neuritis symptoms, improved experimental autoimmune neuritis-induced hyperalgesia and nerve conduction studies, and reduced immune cell infiltration. Furthermore, proteasome inhibition induced a transcriptional downregulation of Nfkb in the sciatic nerve, while its inhibitor Ikba (also known as Nfkbia) was upregulated. Histological analyses of bone marrow tissue revealed a compensatory increase of CD138+ plasma cells. Our data suggest that low dose bortezomib (0.05 mg/kg intraperitoneally) has an immunomodulatory effect in the context of experimental autoimmune neuritis through proteasome inhibition and downregulation of nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NFKB). Higher bortezomib concentrations (0.2 mg/kg intraperitoneally) induce sensory neuropathy; however, the regeneration potential remains unaffected. Our data empathizes that bortezomib may serve as an attractive treatment option for inflammatory neuropathies in lower concentrations.

Metformin Relieves Bortezomib-Induced Neuropathic Pain by Regulating AMPKa2-Mediated Autophagy in the Spinal Dorsal Horn

Metformin Attenuates Bone Cancer Pain by Reducing TRPV1 and ASIC3 Expression

Metformin Relieves Bone Cancer Pain by Reducing TGF(3RI-TRPV1 Signaling in Rats

Metformin relieves bone cancer pain by reducing TGFβRI-TRPV1 signaling in rats

Blocking TRPA1 and TNF-α Signal Improves Bortezomib-Induced Neuropathic Pain.

Metformin Alleviates Pain States by Regulating the Balance of Spinal Synaptic Transmission

Activation of RAGE/STAT3 pathway by methylglyoxal contributes to spinal central sensitization and persistent pain induced by bortezomib

Metformin attenuates diabetic neuropathic pain via AMPK/NF-κB signaling pathway in dorsal root ganglion of diabetic rats

Upregulation of NLRP3 Via STAT3-dependent Histone Acetylation Contributes to Painful Neuropathy Induced by Bortezomib

GATA3-dependent Epigenetic Upregulation of CCL21 is Involved in the Development of Neuropathic Pain Induced by Bortezomib

Reduction of SIRT1 Epigenetically Upregulates NALP1 Expression and Contributes to Neuropathic Pain Induced by Chemotherapeutic Drug Bortezomib

The Actions and Mechanisms of P2X7R and P38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain

The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin

Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neuropathy

Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain

Lysosomal Dysfunction in Schwann Cells is Involved in Bortezomib-Induced Peripheral Neurotoxicity

NFATc2-dependent Epigenetic Downregulation of the TSC2/Beclin-1 Pathway is Involved in Neuropathic Pain Induced by Oxaliplatin

The Possible Involvement of JNK Activation in the Spinal Dorsal Horn in Bortezomib-Induced Allodynia: the Role of TNF-α and IL-1β

AMPK activation attenuates cancer-induced bone pain by reducing mitochondrial dysfunction-mediated neuroinflammation

Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis

Activation of Adenosine Monophosphate–activated Protein Kinase Suppresses Neuroinflammation and Ameliorates Bone Cancer Pain